Signature of profiling and staging the progression of TB from infection to disease.
Signature of profiling and staging the progression of TB from infection to disease.
批准号:
10214482
负责人:
William Evan Johnson
金额:
$20.68万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-10 至 2023-06-30
关键词:
Biological MarkersBlood specimenCessation of lifeClinicalCommunicable DiseasesComputer softwareDataData SetDevelopmentDiagnosticDiseaseDisease ProgressionEtiologyEvaluationFutureGene ExpressionGene Expression ProfileGenesImmunologic FactorsIndividualInfectionLanguageLearningMachine LearningMapsMetadataMethodsModelingMolecularMolecular ProfilingMycobacterium tuberculosisNational Institute of Allergy and Infectious DiseaseOutcomePathogenicityPathway interactionsPatientsPerformancePopulationPulmonary TuberculosisResearchResearch PersonnelResourcesSamplingStagingTechnologyTreatment FailureTreatment ProtocolsTuberculosisValidationVisualizationVisualization softwareWorkbasebiomarker validationcomorbiditycomputational platformdata harmonizationdata toolsdemographicseffective therapyfallsgenetic signaturegenomic biomarkerinteractive toollatent infectionmolecular modelingmolecular pathologymortalitymultiple datasetsnovelpandemic diseaseprediction algorithmscreeningtranscriptome sequencingtreatment responsetreatment riskuser friendly softwareuser-friendly
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Tuberculosis (TB) is the leading cause of infectious disease mortality worldwide. Nearly one-third of the world's
population is infected with Mycobacterium tuberculosis (MTB). More than 10.4 million new cases of active TB
disease develop annually, leading to 1.4 million deaths due to the disease each year. Despite widespread
efforts to study of the etiology of disease, the development and global introduction of an effective treatment
regimen, and sensitive diagnostics for identifying pulmonary TB disease, efforts to control this pandemic are
falling short, largely due to a lack of a clear understanding of the pathogenic progression from MTB infection to
active clinical disease.
In addition, Existing gene expression studies have presented more than three dozen biomarkers to predict TB
related outcomes such as identifying active TB disease, predicting risk of treatment failure, or predicting which
patients will progress to active TB disease. These have been developed and refined using multiple
technologies and using a diverse set of computational and machine learning prediction algorithms, but most
are focused on two-class comparison (e.g. TB vs. LTBI).
In this proposal, we propose to compile and harmonize dozens of existing RNA-sequencing datasets for TB
outcomes. We will use these compiled data to develop a computational platform and interactive visualization
tools for profiling TB signatures across all existing datasets. We plan to use this curated data and software
platform to develop a more refined molecular map of progression from TB infection to active disease.
Consistent with a recently presented models for TB disease development, we hypothesize that we will be able
to identify gene expression patterns associated with stages on the TB disease spectrum, including: uninfected
or eliminated infection, controlled or truly latent infection, future progressors or incipient disease, subclinical TB
disease, and active clinical TB disease. We believe that existing gene expression data and signatures will
allow us to identify distinct transcriptional profiles for each stage, and hence develop a multi-class machine
learning approach for classifying patients into their corresponding stage.
Overall, this proposal contributes to the field by compiling existing gene expression data and developing a
wholistic map of TB progression from infection to active disease. In addition, we will provide a curated dataset
and metadata in an accessible format for more than three dozen existing TB studies, and allow others to
access and explore these data through a user-friendly profiling platform.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1093/biostatistics/kxab039
发表时间:
2023-07-14
期刊:
Biostatistics (Oxford, England)
影响因子:
--
作者:
[]
通讯作者:
Comparison of gene set scoring methods for reproducible evaluation of multiple tuberculosis gene signatures.
用于可重复评估多个结核病基因特征的基因集评分方法的比较。
DOI:
10.1101/2023.01.19.520627
发表时间:
2023
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
作者:
[Wang,Xutao, VanValkenberg,Arthur, Odom-Mabey,AubreyR, Ellner,JerroldJ, Hochberg,NatashaS, Salgame,Padmini, Patil,Prasad, Johnson,WEvan]
通讯作者:
Johnson,WEvan
DOI:
10.1186/s12879-020-05598-z
发表时间:
2021-01-22
期刊:
BMC infectious diseases
影响因子:
3.7
作者:
[Johnson WE, Odom A, Cintron C, Muthaiah M, Knudsen S, Joseph N, Babu S, Lakshminarayanan S, Jenkins DF, Zhao Y, Nankya E, Horsburgh CR, Roy G, Ellner J, Sarkar S, Salgame P, Hochberg NS]
通讯作者:
Hochberg NS
DOI:
10.1038/s41598-023-40799-x
发表时间:
2023-08-26
期刊:
Scientific reports
影响因子:
4.6
作者:
[]
通讯作者:
DOI:
10.3389/fimmu.2022.1011166
发表时间:
2022
期刊:
Frontiers in immunology
影响因子:
7.3
作者:
[]
通讯作者:
共 7 条
Microbiome-based biomarkers and models of lung cancer development and treatment
-
批准号:10739531
-
项目类别:
-
资助金额:$14.56万
-
财政年份:2022
-
负责人:William Evan Johnson
-
依托单位:
Systems Biology Core
-
批准号:10493266
-
项目类别:
-
资助金额:$35.78万
-
财政年份:2021
-
负责人:William Evan Johnson
-
依托单位:
Microbiome-based biomarkers and models of lung cancer development and treatment
-
批准号:10366665
-
项目类别:
-
资助金额:$23.14万
-
财政年份:2021
-
负责人:William Evan Johnson
-
依托单位:
Systems Biology Core
-
批准号:10665023
-
项目类别:
-
资助金额:$35.36万
-
财政年份:2021
-
负责人:William Evan Johnson
-
依托单位:
Systems Biology Core
-
批准号:10271647
-
项目类别:
-
资助金额:$38.47万
-
财政年份:2021
-
负责人:William Evan Johnson
-
依托单位:
Removing batch effects in genomic and epigenomic studies
-
批准号:10155560
-
项目类别:
-
资助金额:$19.4万
-
财政年份:2018
-
负责人:William Evan Johnson
-
依托单位:
Removing batch effects in genomic and epigenomic studies
-
批准号:9926913
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2018
-
负责人:William Evan Johnson
-
依托单位:
Removing batch effects in genomic and epigenomic studies
-
批准号:10739064
-
项目类别:
-
资助金额:$12.05万
-
财政年份:2018
-
负责人:William Evan Johnson
-
依托单位:
Removing batch effects in high-throughput biomedical studies
-
批准号:10659898
-
项目类别:
-
资助金额:$30.08万
-
财政年份:2018
-
负责人:William Evan Johnson
-
依托单位:
An interactive analysis toolkit for single cell RNA-seq in cancer research
-
批准号:9389818
-
项目类别:
-
资助金额:$39.8万
-
财政年份:2017
-
负责人:William Evan Johnson
-
依托单位:
An interactive analysis toolkit for single cell RNA-seq in cancer research
-
批准号:9751823
-
项目类别:
-
资助金额:$45.63万
-
财政年份:2017
-
负责人:William Evan Johnson
-
依托单位:
Integrative analyses of reference epigenomic maps and applications
-
批准号:8815813
-
项目类别:
-
资助金额:$33.74万
-
财政年份:2014
-
负责人:William Evan Johnson
-
依托单位:
Statistical Tools and Methods for Next-Generation Sequencing in Epigenetics
-
批准号:8451427
-
项目类别:
-
资助金额:$32.11万
-
财政年份:2010
-
负责人:William Evan Johnson
-
依托单位:
Methods for the analysis and integrations of next-generation sequencing with appl
-
批准号:7865503
-
项目类别:
-
资助金额:$34.97万
-
财政年份:2010
-
负责人:William Evan Johnson
-
依托单位:
Statistical Tools and Methods for Next-Generation Sequencing in Epigenetics
-
批准号:8235963
-
项目类别:
-
资助金额:$33.61万
-
财政年份:2010
-
负责人:William Evan Johnson
-
依托单位:
Methods for the analysis and integrations of next-generation sequencing with appl
-
批准号:8078848
-
项目类别:
-
资助金额:$33.38万
-
财政年份:2010
-
负责人:William Evan Johnson
-
依托单位:
海外基金